• Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it.
• The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today.
• Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory progress. This helps explain why the share price has stayed in focus for many investors. There has also been ongoing discussion about how its portfolio fits into broader healthcare trends, adding another layer to how the market is thinking about risk and reward.
• On Simply Wall St's valuation checks, United Therapeutics scores 4 out of 6. The next step is a closer look at how different valuation methods line up on the stock, and why there may be an even better way to frame its value by the end of this article.

Approach 1: United Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, takes projected future cash flows and discounts them back to today to estimate what the entire company could be worth in present dollar terms. It is essentially asking what those future streams of cash are worth right now.

For United Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s latest twelve month free cash flow sits at about $1.17b. Analysts provide explicit free cash flow estimates out to 2030, with Simply Wall St extending these projections further using its own assumptions. By 2035, the extrapolated annual free cash flow in the model reaches around $4.02b, with interim projections stepping up through the late 2020s and early 2030s.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $1,741.59 per share. Against the recent share price of around $596.76, this suggests the stock is trading at a 65.7% discount on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests United Therapeutics is undervalued by 65.7%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: United Therapeutics Price vs Earnings

For profitable companies, the P/E ratio is a useful shortcut because it links what you pay for the stock to what the business currently earns. It helps you see how many dollars of share price the market is assigning to each dollar of earnings.

What counts as a normal or fair P/E typically reflects how fast earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can support a higher multiple, while lower growth or higher risk usually point to a lower multiple.

United Therapeutics currently trades at about 20.32x earnings. That sits above the broader Biotechs industry average of 17.76x but below the peer average of 31.11x. Simply Wall St’s Fair Ratio for United Therapeutics is 23.45x, which is its proprietary view of what a balanced P/E should be after factoring in elements such as earnings growth, profitability, industry, market cap and risk profile.

This Fair Ratio can be more informative than a simple industry or peer comparison because it adjusts for company specific traits rather than assuming all biotechs should trade on the same multiple. With the current P/E of 20.32x below the Fair Ratio of 23.45x, the stock screens as trading below that implied fair level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your United Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take that next step by letting you pair a clear story about United Therapeutics with your own forecast for revenue, earnings and margins. This then links through to a Fair Value that you can compare with the current share price and update easily on Simply Wall St’s Community page whenever fresh news or earnings arrive. You can see the company closer to the lower fair value of about US$519 with modest 3.5% annual revenue growth and margins easing to 39.0%, or nearer to the higher fair value near US$645 with faster 17.0% modeled revenue growth and margins around 49.7%.

For United Therapeutics, however, we will make it really easy for you with previews of two leading United Therapeutics Narratives:

Think of these as two bookends for what the stock could be worth, depending on how you see the pipeline, competition and future earnings playing out. One sits closer to the more optimistic analyst camp, the other anchors the cautious end of the range.

Fair value in this narrative: US$644.08

Implied discount vs last close of US$596.76: about 7.4% undervalued

Assumed annual revenue growth: 11.12%

• Analysts in this camp lean on positive clinical data for Tyvaso in idiopathic pulmonary fibrosis, ralinepag and organ technologies as potential drivers of a larger pulmonary and regenerative medicine business over time.
• The story assumes a strong balance sheet and close to US$1.5b in annual operating cash flow can comfortably fund R&D, share buybacks and product launches while still supporting earnings.
• Key risks flagged include heavier R&D spend, clinical trial uncertainty, competitive pressure in pulmonary arterial hypertension and ongoing drug pricing scrutiny, any of which could upset the growth and margin profile that underpins the US$644 fair value.

Fair value in this narrative: US$519.00

Implied premium vs last close of US$596.76: about 15.0% overvalued

Assumed annual revenue growth: 3.53%

• This view leans into concentration risk in Tyvaso and Remodulin, with patent expiries, generics and biosimilars seen as key threats that could weigh on revenue once exclusivity fades.
• It also treats organ manufacturing and xenotransplantation as high cost, high uncertainty projects that may take longer to contribute, which keeps assumed revenue growth and margins lower than consensus.
• Supportive factors such as the Tyvaso franchise, late stage pulmonary trials and a sizeable buyback are acknowledged, but the conclusion is that these positives are already largely reflected in a fair value of about US$519.

Together, these two narratives frame a range from roughly US$519 to US$644 that you can use as a starting point when testing your own assumptions on growth, margins and risk for United Therapeutics.

Do you think there's more to the story for United Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.